Yield10 Bioscience stock posts a 2026 revenue decline

Yield10 Bioscience stock is tied to a 2026 sales figure of USD 60,000, down 86.67 percent from USD 450,000 in 2025. The figures, dated September 17, 2026, show a company whose listed operating scale remains small relative to its reported cost base.

Revenue drops to USD 60,000

According to Eulerpool, Yield10 Bioscience revenue is listed at USD 60,000 for 2026 versus USD 450,000 for 2025. That USD 390,000 decline equals 86.67 percent and is the clearest quantified signal in the available company data.

The same data page describes the 2026 figure as part of a longer revenue series. For investors, the comparison matters because the absolute revenue base is far below the company's listed expense and liability figures.

Losses and liabilities remain material

Eulerpool lists 2026 EBIT at negative USD 14.42 million, compared with negative USD 13.45 million for 2025. The USD 970,000 wider operating loss reinforces the gap between revenue generation and operating costs.

Liabilities are listed at USD 6.39 million for 2026, up 72.70 percent from USD 3.70 million in the prior year, according to Eulerpool. The increase adds balance-sheet pressure to the revenue comparison.

Small workforce underscores scale

Yield10 Bioscience is listed with 30 employees in 2026, unchanged from 30 in 2025, according to Eulerpool. The unchanged headcount alongside USD 60,000 in listed revenue provides a concrete measure of the company's current operating footprint.

Yield10 Bioscience describes itself as an agricultural bioscience company and identifies the OTCQB ticker YTEN in its investor-relations materials dated November 8, 2024, Yield10 Bioscience.

Revenue decline defines the picture

Yield10 Bioscience stock is framed by USD 60,000 in listed 2026 revenue, a 86.67 percent year-over-year decline, and negative USD 14.42 million in EBIT. Those figures make operating scale and balance-sheet development the central reference points for the company.